Navigation Links
Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians' Antibiotic Selection for Nosocomial Pneumonia in the U.S.

MALVERN, Pa., Nov. 2, 2010 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the leading driver of antibiotic selection in nosocomial pneumonia in the United States is activity against key drug-resistant pathogens. Such pathogens include P. aeruginosa, MRSA, Vancomycin-resistant Staphylococcus aureus and multidrug-resistant Steptococcus pneumonia.

"Nosocomial pneumonia is one of the most important indications for hospital antibiotics in the U.S. because of its relatively high morbidity and mortality and high frequency of drug-resistant pathogens," stated James Andersen, analyst at AMR.

In the new report entitled Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia, surveyed physicians indicate that the excellent bactericidal activity and lung penetration of Pfizer's Zosyn are primary reasons for its success in the nosocomial pneumonia drug market, while Pfizer's success with Zyvox is largely driven by its convenient availability in a dual IV/oral formulation. Johnson & Johnson's success with Levaquin is driven by a high level of experience among surveyed physicians, relatively high activity against nosocomial pneumonia pathogens, low dosing frequency and dual IV/oral formulation.

About the Report

AMR's Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with primary research and extensive understanding of emerging therapies and forecasts. This report contains U.S. data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Arlington Medical Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
3. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
4. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
5. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
6. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
7. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
8. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
11. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
Post Your Comments:
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)...  Henry Schein, Inc., the world,s largest provider of ... and animal health practitioners, will unveil at the Greater ... ConnectDental® Pavilion , which brings together for the first ... to help any practice or laboratory enter the digital ... schedule of experts appearing at the Pavilion. --> ...
Breaking Medicine Technology:
(Date:11/28/2015)... Viejo, CA (PRWEB) , ... November 28, 2015 , ... ... new fully customizable media panels to choose from, the possibilities are endless. Users have ... and more. With the ProPanel: Pulse masking effects, users are sure to get heads ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
Breaking Medicine News(10 mins):